Serial No.: 10/719,429

Filing Date: November 21, 2003

Office Action Dated: September 19, 2007

Reply Date: May 8, 2008

## Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

## **Listing of Claims:**

## 1-10. (Canceled)

11. (Currently Amended<sup>1</sup>) The A compound of claim 5 according to the structure

$$\bigcap_{N \in \mathcal{N}} R_4$$

wherein at least one of R2, R3 or R4 is OH and and at least one of R2, R3

wherein R<sub>4</sub> or R<sub>5</sub> is NO<sub>2</sub> and the other of R<sub>4</sub> or R<sub>5</sub> is H,

or a pharmaceutically acceptable salt thereof.

; or wherein at least one of R<sub>2</sub>, R<sub>3</sub> and R<sub>4</sub> is OH, at least one of R<sub>2</sub>, R<sub>3</sub> R<sub>4</sub>, R<sub>5</sub> or R<sub>6</sub> is the alkyl, and R<sub>4</sub> is SO<sub>2</sub>CH<sub>3</sub>, SO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, SO<sub>2</sub>(CH<sub>2</sub>)<sub>2</sub>CH<sub>3</sub> or SO<sub>2</sub>(CH<sub>2</sub>)<sub>3</sub>CH<sub>3</sub>.

## 12-18. (Canceled)

19. (Currently Amended) A method of inducing apoptosis in human breast cancer cells comprising contacting the cancer cell with the compound of <u>claim 11</u> any one of claims 5-17.

<sup>&</sup>lt;sup>1</sup> In the Reply dated June 19, 2007, claim 11 was incorrectly noted as being "Original." The status should have been "Currently Amended."

Serial No.: 10/719,429

Filing Date: November 21, 2003

Office Action Dated: September 19, 2007

Reply Date: May 8, 2008

20. (Currently Amended) A method of treating human breast cancer in a subject in need of said treatment, comprising administering to the subject the compound of <u>claim 11</u> any one of claims 5-17.

- 21. (Original<sup>2</sup>) The method of claim 20 wherein said method further comprises administering calcium glucarate to the subject.
- 22. (New) The compound of claim 11, wherein the salt is a hydrochloride salt or a pyridine salt.
  - 23. (New) A pharmaceutical composition comprising: a compound according to the structure

$$\bigcap_{N \in \mathcal{A}} R_{5}$$

wherein  $R_4$  or  $R_5$  is  $NO_2$  and the other of  $R_4$  or  $R_5$  is H, or a pharmaceutically acceptable salt thereof, and, a pharmaceutically acceptable carrier.

<sup>&</sup>lt;sup>2</sup> Claim 21 should not be withdrawn because is depends from claim 20, which is not withdrawn, and because claim 21 merely adds an additional step.